Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Elias J JabbourDaniel J DeAngeloMatthias StelljesWendy StockMichaela LiedtkeNicola GökbugetSusan M O'BrienTao WangM Luisa PaccagnellaBarbara SleightErik VandendriesAnjali S AdvaniHagop M KantarjianPublished in: Cancer (2018)
InO was tolerable in older patients with relapsed/refractory ALL. Although OS was longer for younger patients versus older patients, InO demonstrated high response rates with similar DOR in the 2 age groups. Cancer 2018;124:1722-32. © 2018 American Cancer Society.
Keyphrases
- acute lymphoblastic leukemia
- papillary thyroid
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- squamous cell
- acute myeloid leukemia
- diffuse large b cell lymphoma
- newly diagnosed
- ejection fraction
- chronic kidney disease
- hodgkin lymphoma
- prognostic factors
- peritoneal dialysis
- lymph node metastasis
- squamous cell carcinoma
- physical activity
- childhood cancer